Skip to content


VIC aims to advance research initiatives efficiently from discovery through the preclinical stage to early clinical testing to enable successful product development by an industry or a non-profit partner.

There are now 9 novel medical products under development at VIC targeting specific cancers, infectious and immune mediated diseases including mesothelioma, Q fever and type 1 diabetes. These products are broadly applicable and include devices, cell therapies and the repurposing of immunomodulatory small molecules and the invention of biologics.

The model encompasses:

  • Innovative translational bench to bedside science team
  • Training and career development for next generation of translational scientists
  • Distributed development with best in class collaborators
  • Assiduous project management and product development
  • Position projects for effective translational hand-off, including foundation for regulatory review
  • Diversified funding portfolio